Skip to main content
Sudeep Pharma Limited logo

Sudeep Pharma Limited — Investor Relations & Filings

Ticker · SUDEEPPHRM ISIN · INE0QPI01025 LEI · 335800ESH1W57DIPAN45 BSE.NS Manufacturing
Open in API
Filings indexed 75 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS SUDEEPPHRM

About Sudeep Pharma Limited

https://www.sudeeppharma.com/

Sudeep Pharma Limited specializes in the manufacturing of mineral-based excipients and active pharmaceutical ingredients (APIs). The company’s core portfolio includes high-purity mineral salts such as Calcium Phosphates, Calcium Carbonate, and Calcium Sulfate, which are utilized as essential components in solid dosage formulations and nutritional supplements. These products function as diluents, binders, and mineral sources across various applications. The organization maintains advanced production facilities compliant with international quality standards, including GMP, USP, EP, and BP. A strategic partnership with JRS Pharma enhances its technical expertise and global supply chain capabilities. Sudeep Pharma focuses on providing high-quality, regulatory-compliant mineral solutions to meet the demands of global markets, emphasizing research, development, and stringent quality control processes.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is an intimation letter to stock exchanges under SEBI Listing Regulations (Regulation 30) disclosing the schedule of analyst/institutional investor meetings. It is a mandatory regulatory announcement and contains no financial statements, presentation slides, or transcripts. It does not fit into any specific category like earnings release, investor presentation, or management change, so it falls into the general Regulatory Filings category (RNS).
2026-05-23 English
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended from time to time, we herewith submit the participation of Company Officials ....
Regulatory Filings Classification · 85% confidence The document is an intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30, notifying stock exchanges of the schedule of analyst and institutional investor meetings. It does not contain financial results or substantive report content, nor is it a proxy, dividend notice, earnings release, or investor presentation. This is a regulatory announcement/disclosure under continuous listing obligations, fitting the general Regulatory Filings (RNS) category.
2026-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI Listing Regulations notifying the stock exchanges that the audio recording of an earnings call has been uploaded to the company’s website. It does not contain any substantive financial data or the actual earnings release/transcript itself; it is a compliance announcement. Therefore, it fits the “Regulatory Filings (RNS)” category as a general regulatory announcement under listing rules.
2026-05-22 English
Submission of Audio Recording of Investor''s Call/Meet held on 22nd May 2026 at 11:00 a.m.
Regulatory Filings Classification · 95% confidence The document is a brief regulatory disclosure letter under SEBI Listing Regulation 30 informing stock exchanges that the audio recording of the Q4 earnings call has been uploaded and that the transcript will follow separately. It does not contain the actual financial results or transcript, nor is it the full earnings call transcript itself. It is a compliance filing to the exchange, which falls under the general Regulatory Filings category rather than an earnings release or report. Therefore, the correct classification is RNS (Regulatory Filings).
2026-05-22 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 92% confidence The document is a letter to stock exchanges under SEBI (LODR) regulations stating that the company has published extracts of its audited financial results (Q4 and FY ended March 31, 2026) in newspapers and provided a QR code/link on its website. It does not itself contain full financial statements but announces the publication of those results. According to the ‘menu vs meal’ rule and the definition of Report Publication Announcement (RPA), this is an announcement regarding the release/publication of a report rather than the report itself.
2026-05-22 English
Pursuant to Regulation 30 and 47 of the SEBI LODR Regulation, we hereby submit the copies of the extract of audited financials results of the Company for the 4th Quarter and year ended ....
Report Publication Announcement Classification · 85% confidence The document is a compliance letter from Sudeep Pharma Limited to the NSE and BSE under SEBI LODR Regulations 30 and 47, notifying the exchanges that the extract of the audited financial results for Q4 and FY ended 31 March 2026 has been published in newspapers and is available on the company’s website. It contains no substantive financial statements itself but simply announces the publication of the report extract. This matches the definition of a Report Publication Announcement (RPA).
2026-05-22 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.